Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours

Ken Uchino, Andrei Alexandrov, Zsolt Garami, Ashraf El-Mitwalli, Lewis B. Morgenstern, James C. Grotta

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: The most common reason that patients do not receive intravenous tissue plasminogen activator (TPA) is the inability to meet the strict 3-hour treatment window. The risk/benefit ratio is more unfavorable beyond this time, but some patients might still benefit. We designed a pilot study with the hypothesis that lower dose TPA might be safe in selected patients treated beyond 3 h. Subjects and Methods: To determine the range of symptomatic hemorrhage and good outcome, we prospectively gave IV TPA 0.6mg/kg up to 60 mg (15% bolus, 85% infusion over 30 min) to patients with ischemic stroke beyond the first 3 h after last known to be normal. Other eligibility criteria were: NIH Stroke Scale > 4, normal head CT scan, and clinical suspicion or transcranial Doppler (TCD) evidence of a proximal arterial occlusion. Results: 28 patients were treated, median age 65 (range 24-88) years, median baseline NIHSS score 18 (range 7-34) points. TPA bolus was given 372 ± 158 min after stroke onset (range 189-720). Symptomatic hemorrhage occurred in 3/28 (11%) patients, including 1 fatal bleed. Overall mortality was 6/28 (21%). Partial or complete recanalization was found in 8/20 (40%) TCD monitored patients within 2 h after TPA bolus. Early major improvement occurred in 4/28 (14%) patients. Conclusions: Lower dose IV TPA in patients presenting beyond 3 h carries a risk of intracerebral hemorrhage. However, recanalization with dramatic recovery can still occur.

Original languageEnglish (US)
Pages (from-to)260-266
Number of pages7
JournalCerebrovascular Diseases
Volume19
Issue number4
DOIs
StatePublished - May 11 2005

Fingerprint

Tissue Plasminogen Activator
Stroke
Safety
Therapeutics
Hemorrhage
Cerebral Hemorrhage
Odds Ratio
Head
Mortality

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours. / Uchino, Ken; Alexandrov, Andrei; Garami, Zsolt; El-Mitwalli, Ashraf; Morgenstern, Lewis B.; Grotta, James C.

In: Cerebrovascular Diseases, Vol. 19, No. 4, 11.05.2005, p. 260-266.

Research output: Contribution to journalArticle

Uchino, Ken ; Alexandrov, Andrei ; Garami, Zsolt ; El-Mitwalli, Ashraf ; Morgenstern, Lewis B. ; Grotta, James C. / Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours. In: Cerebrovascular Diseases. 2005 ; Vol. 19, No. 4. pp. 260-266.
@article{5fe6bba3a174455dba79159a5cfa2e2c,
title = "Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours",
abstract = "Background: The most common reason that patients do not receive intravenous tissue plasminogen activator (TPA) is the inability to meet the strict 3-hour treatment window. The risk/benefit ratio is more unfavorable beyond this time, but some patients might still benefit. We designed a pilot study with the hypothesis that lower dose TPA might be safe in selected patients treated beyond 3 h. Subjects and Methods: To determine the range of symptomatic hemorrhage and good outcome, we prospectively gave IV TPA 0.6mg/kg up to 60 mg (15{\%} bolus, 85{\%} infusion over 30 min) to patients with ischemic stroke beyond the first 3 h after last known to be normal. Other eligibility criteria were: NIH Stroke Scale > 4, normal head CT scan, and clinical suspicion or transcranial Doppler (TCD) evidence of a proximal arterial occlusion. Results: 28 patients were treated, median age 65 (range 24-88) years, median baseline NIHSS score 18 (range 7-34) points. TPA bolus was given 372 ± 158 min after stroke onset (range 189-720). Symptomatic hemorrhage occurred in 3/28 (11{\%}) patients, including 1 fatal bleed. Overall mortality was 6/28 (21{\%}). Partial or complete recanalization was found in 8/20 (40{\%}) TCD monitored patients within 2 h after TPA bolus. Early major improvement occurred in 4/28 (14{\%}) patients. Conclusions: Lower dose IV TPA in patients presenting beyond 3 h carries a risk of intracerebral hemorrhage. However, recanalization with dramatic recovery can still occur.",
author = "Ken Uchino and Andrei Alexandrov and Zsolt Garami and Ashraf El-Mitwalli and Morgenstern, {Lewis B.} and Grotta, {James C.}",
year = "2005",
month = "5",
day = "11",
doi = "10.1159/000084090",
language = "English (US)",
volume = "19",
pages = "260--266",
journal = "Cerebrovascular Diseases",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours

AU - Uchino, Ken

AU - Alexandrov, Andrei

AU - Garami, Zsolt

AU - El-Mitwalli, Ashraf

AU - Morgenstern, Lewis B.

AU - Grotta, James C.

PY - 2005/5/11

Y1 - 2005/5/11

N2 - Background: The most common reason that patients do not receive intravenous tissue plasminogen activator (TPA) is the inability to meet the strict 3-hour treatment window. The risk/benefit ratio is more unfavorable beyond this time, but some patients might still benefit. We designed a pilot study with the hypothesis that lower dose TPA might be safe in selected patients treated beyond 3 h. Subjects and Methods: To determine the range of symptomatic hemorrhage and good outcome, we prospectively gave IV TPA 0.6mg/kg up to 60 mg (15% bolus, 85% infusion over 30 min) to patients with ischemic stroke beyond the first 3 h after last known to be normal. Other eligibility criteria were: NIH Stroke Scale > 4, normal head CT scan, and clinical suspicion or transcranial Doppler (TCD) evidence of a proximal arterial occlusion. Results: 28 patients were treated, median age 65 (range 24-88) years, median baseline NIHSS score 18 (range 7-34) points. TPA bolus was given 372 ± 158 min after stroke onset (range 189-720). Symptomatic hemorrhage occurred in 3/28 (11%) patients, including 1 fatal bleed. Overall mortality was 6/28 (21%). Partial or complete recanalization was found in 8/20 (40%) TCD monitored patients within 2 h after TPA bolus. Early major improvement occurred in 4/28 (14%) patients. Conclusions: Lower dose IV TPA in patients presenting beyond 3 h carries a risk of intracerebral hemorrhage. However, recanalization with dramatic recovery can still occur.

AB - Background: The most common reason that patients do not receive intravenous tissue plasminogen activator (TPA) is the inability to meet the strict 3-hour treatment window. The risk/benefit ratio is more unfavorable beyond this time, but some patients might still benefit. We designed a pilot study with the hypothesis that lower dose TPA might be safe in selected patients treated beyond 3 h. Subjects and Methods: To determine the range of symptomatic hemorrhage and good outcome, we prospectively gave IV TPA 0.6mg/kg up to 60 mg (15% bolus, 85% infusion over 30 min) to patients with ischemic stroke beyond the first 3 h after last known to be normal. Other eligibility criteria were: NIH Stroke Scale > 4, normal head CT scan, and clinical suspicion or transcranial Doppler (TCD) evidence of a proximal arterial occlusion. Results: 28 patients were treated, median age 65 (range 24-88) years, median baseline NIHSS score 18 (range 7-34) points. TPA bolus was given 372 ± 158 min after stroke onset (range 189-720). Symptomatic hemorrhage occurred in 3/28 (11%) patients, including 1 fatal bleed. Overall mortality was 6/28 (21%). Partial or complete recanalization was found in 8/20 (40%) TCD monitored patients within 2 h after TPA bolus. Early major improvement occurred in 4/28 (14%) patients. Conclusions: Lower dose IV TPA in patients presenting beyond 3 h carries a risk of intracerebral hemorrhage. However, recanalization with dramatic recovery can still occur.

UR - http://www.scopus.com/inward/record.url?scp=17844384572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844384572&partnerID=8YFLogxK

U2 - 10.1159/000084090

DO - 10.1159/000084090

M3 - Article

VL - 19

SP - 260

EP - 266

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 4

ER -